In an effort to determine if lowering the RPA threshold with 551 would result in a synergy with DNA-damaging agents like platinum (Pt)-based drugs, in vivo efficacy studies were performed in non-small cell lung cancer (NSCLC) xenograft models. The gene discussed is RPA1; the disease is non-small cell lung carcinoma.